Developer docs
API playgroundTry for free, no card

Search company profiles

BMG Pharma

Full company profile

uuid0003pom

Namestring
BMG Pharma
Legal namestring
BMG Pharma SpA
Websiteurl
bmgpharma.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

BMG Pharma SpA is a privately-held Italian pharmaceutical and biotechnology company headquartered in Milan with a dedicated chemical plant and R&D center in Torviscosa, Friuli Venezia Giulia. The company develops and licenses biomaterials derived from modified hyaluronic acid (HA) using its proprietary Hyaluromimethic® technology platform, which performs covalent modification of HA at hydroxyl residues with functional, biologically active molecules. This produces a modular family of derivatives including Sodium Hyaluronate Butyrate (SHB), Sodium Hyaluronate Lipoate (SHL), Sodium Hyaluronate Lipoate Formate (SHLF), and Zinc-Gluconate combinations, each with distinct physicochemical properties tailored for specific applications. The company holds 140 patents across 9 patent families and 6 international brands, and operates four business units: BMG Biochemical (raw materials, recently spun off as an independent entity), BMG Bioaesthetic (Class III injectable aesthetic devices), BMG Therapeutics (Class III injectable orthopedic and ophthalmological devices including SGA400), and BMG Dermacare (professional cosmetic products under the HYALUVANCE® brand).

The business operates an asset-light B2B model combining raw materials supply, technology licensing, and co-development partnerships with international pharmaceutical and cosmetic companies. Production of finished products and clinical consultancy are outsourced to contract manufacturing organizations (CMOs), while marketing is conducted through international distribution partners. The customer base spans oral care (Dompè, Pierre Fabre, ISDIN, Polifarma, Bionativa, Sophos, Galen, Diomed Dermal), dermatology (Difa Cooper, Dr Gorkic), and aesthetic medicine, with finished products marketed under partner brands such as Euclorina, Elgydium, Bexident, Emoform, and GelX. The company's go-to-market combines enterprise field sales to pharma partners with direct engagement of health professionals (aesthetic doctors, nurses) for the HYALUVANCE® professional cosmetic line.

Current commercial focus is on scaling the Class III injectable pipeline (six dermal fillers and one orthopedic injectable in clinical/MDR regulatory stages in Europe), launching HYALUVANCE® Golden for aesthetic medicine mesotherapy, and licensing the Hyaluromimethic® platform to global pharmaceutical partners. The company is ISO 13485 certified and pursues European MDR registration through Notified Bodies TÜV and Eurofins. Revenue figures are not publicly disclosed, and the company remains privately held following minority investments from Massimo Doris (CEO of Banca Mediolanum, 2% stake acquired November 2022) and Friulia Finanziaria FVG (regional PE firm, ~$2.4M round in 2021).

Short descriptiontext

BMG Pharma is an Italian pharmaceutical company that develops and licenses proprietary modified hyaluronic acid biomaterials (Hyaluromimethic® platform) through B2B partnerships with global pharmaceutical and cosmetic companies serving aesthetic, orthopedic, ophthalmic, dermatological, and oral care markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMilan, Italy
HQ citystring
Milan
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hyaluronic acid biomaterials, pharmaceutical product development, medical device manufacturing, biotechnology licensing, aesthetic medicine products
Industry3 codes
PRIMARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYIMANABAK
Medical & Food-Contact Specialty Compounds
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Surgical & Medical Instruments & Apparatus3841
Product category
Biopharmaceuticals & Medical Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Licensing/Property
TypeLicensing Royalties
Description

Patents; ISO 13485 TUV Sud certification for medical devices; Know-how and technology licensing. Hyaluronic acid derivatives production plant; Marketing of raw materials through collaborations with international pharmaceutical companies.

bmgpharma.com
2Aesthetic Applications Products
TypeOne Time License
Description

Licensing of aesthetic applications of injectable products based on hyaluronic acid butyrate derivatives (SHB) and lipoates (SHLF) with the international brand Hyaluromimethic®. 6 dermal fillers undergoing clinical trials and MDR registration in Europe.

bmgpharma.com
3Orthopaedic Applications
TypeOne Time License
Description

Licensing of orthopaedic applications of injectable products based on hyaluronic acid lipoate derivative (SHLF). 1 injectable in preclinical investigation phase for MDR registration.

bmgpharma.com
4Professional Cosmetics
TypeHardware Sales
Description

Sale of cosmetics for professional use by aesthetic doctors with the international proprietary brand HYALUVANCE®. HYALUVANCE® GOLDEN available for marketing.

bmgpharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1HYALUVANCE®
Description

International brand for professional cosmetic products for aesthetic medicine, including sterile topical products and the HYALUVANCE® GOLDEN line based on milk exosomes, type 3 collagen, and polynucleotides

bmgpharma.com
+6 more records
Core offering1 text field

BMG Pharma develops, manufactures, and licenses innovative biomaterials based on its proprietary Hyaluromimethic® technology platform, which enables covalent modification of hyaluronic acid at hydroxyl residues with functional, biologically active molecules. The company produces hyaluronic acid derivative raw materials (SHB, SHL, SHLF, SHLFZ), Class III injectable medical devices (SGA400 for osteoarthritis; dermal fillers), and professional cosmetic products (HYALUVANCE® line for aesthetic medicine), serving global pharmaceutical partners and health professionals through licensing, contract manufacturing, and direct distribution.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 4 new patents created and 36 innovative products registered, 37 launched internationally in two years
+1 more record
Product overview1 text field

BMG Pharma is a pharmaceutical company with over 15 years of experience developing and partnering internationally on innovative medical products. The company has developed the proprietary Hyaluromimethic® technology platform for covalent modification of hyaluronic acid, which serves as the foundation for its product ecosystem. The portfolio includes four business units: BMG Biochemical (chemical technology hub producing functional ingredients and raw materials like SHB, SHL, SHLF derivatives), BMG Bioaesthetic (Class III injectable medical devices for aesthetic medicine), BMG Therapeutics (Class III injectable medical devices for orthopedics and ophthalmology, including SGA400), and BMG Dermacare (professional topical cosmetic products under the HYALUVANCE® brand including HYALUVANCE® Golden). The company also licenses its technology and holds 140 patents across 9 families globally.

Product and service6 records
1Hyaluromimethic® Technology Platform
CategoryTechnology Platform / Licensed IP
Description

Proprietary patented technology platform for covalent modification of hyaluronic acid at hydroxyl residues with functional, biologically active molecules. Licensed to pharmaceutical partners for the development of biomaterials, medical devices, and cosmetic products in aesthetic, orthopedic, ophthalmological, and dermatological applications.

2SGA400
CategoryMedical Device (Class III Injectable)
Description

Class 3 medical injectable based on Hyaluromimethic® technology for intraarticular therapy. Provides long intra-articular permanence, absorption of mechanical stress, modulation of inflammation and free radicals, and pain management for patients suffering from joint osteoarthritis.

3HYALUVANCE® Golden
CategoryProfessional Cosmetic Product
Description

Sterile cosmetic vials (5x3ml) for professional use in aesthetic medicine. Based on milk exosomes, type 3 collagen, polynucleotides (PDRN), and high molecular weight hyaluronic acid. Indicated for skin rejuvenation mesotherapy treatments.

4HYALUVANCE® Professional Cosmetics Line
CategoryProfessional Cosmetic Product Line
Description

International proprietary brand under which a new pipeline of professional cosmetic products for aesthetic medicine is being built. Includes sterile topical products distributed through BMG Dermacare for medical professionals offering innovative aesthetic treatments.

5Hyaluronic Acid Derivative Raw Materials (SHB, SHL, SHLF, SHLFZ)
CategoryRaw Materials / Active Pharmaceutical Ingredients
Description

Functional hyaluronic acid derivative raw materials produced by BMG Biochemical and supplied to pharmaceutical partners. Includes Sodium Hyaluronate Butyrate (SHB), Sodium Hyaluronate Lipoate (SHL), Sodium Hyaluronate Lipoate Formate (SHLF), and Sodium Hyaluronate Lipoate Formate and Zinc Gluconate (SHLFZ) — each with distinct functional properties for dermatology, tissue repair, aesthetic, and medical applications.

6Hyaluromimethic® Dermal Fillers Pipeline (6 products in clinical trials/MDR registration)
CategoryMedical Device (Class III Injectable) — Aesthetic
Description

Licensed aesthetic application injectable products based on Hyaluromimethic® hyaluronic acid derivatives (SHB and SHLF). Six dermal fillers currently in clinical trials and MDR registration in Europe for aesthetic dermatology and biorevitalization applications.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Allianz PowerVolley Milano
Strategic tierMinorTypeOthersAnnounced on2026-04-03
Description

BMG Pharma has always supported Allianz PowerVolley Milano volleyball team. The team won the 2026 CEV Challenge Cup. The company aims to bring prominent volleyball back to Milan.

bmgpharma.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-09-15
Description

BMG Pharma and HTL Biotechnology signed an agreement for the production of the functional ingredient underlying the patented Hyaluromimethic® technology. This partnership ensures production capability for the exclusive technology platform.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Dompé Farmaceutici
TypeEmerging player
Description

Italian pharma with a board connection to BMG and a disclosed BMG customer using its ingredients in oral-care ranges. Comparable as a like-for-like Italian specialty pharma and existing commercial partner for BMG's technology.

TypeBroad incumbent
Description

Global dermatology and aesthetic medicine leader selling hyaluronic-acid-based dermal fillers (Restylane, Emervel) and prescription aesthetics. Directly comparable to BMG Bioaesthetic and HYALUVANCE® as the incumbent BMG is trying to disrupt in fillers and professional aesthetic skincare.

TypeBroad incumbent
Description

Subsidiary of Merz Pharma marketing hyaluronic acid fillers (Belotero), biostimulators and medical skincare. Competes head-on with BMG Bioaesthetic and HYALUVANCE® in clinic-administered aesthetics.

TypeDirect peer
Description

Italian specialty pharma whose hyaluronic acid-based products (e.g. Hyalgan, Hymovis) cover intra-articular osteoarthritis therapy and aesthetic medicine. Direct category overlap with BMG Therapeutics' SGA400 and the BMG Bioaesthetic injectable line.

TypeDirect peer
Description

Aesthetic medicine company previously LSE-listed, founded by BMG's current CEO Marco Mastrodonato. Sells hyaluronic-acid dermal fillers and collagen-stimulating injectables (e.g. Ellansé, MaiLi). Same hyaluronic-acid-based injectable franchise, same end customer (aesthetic physicians), making it the closest direct comparable.

TypeOthers
Description

French-Japanese specialist manufacturer of high-purity hyaluronic acid for medical and aesthetic applications. Signed a 2022 production agreement with BMG, making it a critical supplier/partner rather than a competitor, but a highly relevant comparable for understanding HA ingredient economics.

TypeDirect peer
Description

Swiss manufacturer of hyaluronic acid-based dermal fillers (Teosyal RHA range) and professional cosmeceuticals. Overlaps with BMG Bioaesthetic's injectable pipeline and HYALUVANCE® professional skincare in the same clinician-administered channel.

TypeDirect peer
Description

US-based developer of hyaluronic acid-based intra-articular and regenerative products (e.g. Monovisc, Orthovisc, Cingal) for osteoarthritis and tendon repair, plus aesthetic HA offerings. The cleanest US analog to BMG Therapeutics' SGA400 program.

TypeDirect peer
Description

Italian private pharma company with a substantial hyaluronic acid portfolio including intra-articular injectables for osteoarthritis and aesthetic dermatology products. Closely comparable to BMG Therapeutics (SGA400 osteoarthritis injectable) and BMG Bioaesthetic.

10Revance Therapeutics
TypeEmerging player
Description

US aesthetics-focused biotech whose portfolio includes the RHA Collection of hyaluronic acid fillers following the Teoxane US acquisition. Comparable business model — innovator aesthetics platform leveraging differentiated HA technology — to BMG Bioaesthetic.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BMG Pharma

Biopharmaceuticals & Medical Devicesbmgpharma.com

BMG Pharma is an Italian pharmaceutical company that develops and licenses proprietary modified hyaluronic acid biomaterials (Hyaluromimethic® platform) through B2B partnerships with global pharmaceutical and cosmetic companies serving aesthetic, orthopedic, ophthalmic, dermatological, and oral care markets.

What BMG Pharma does

BMG Pharma SpA is a privately-held Italian pharmaceutical and biotechnology company headquartered in Milan with a dedicated chemical plant and R&D center in Torviscosa, Friuli Venezia Giulia. The company develops and licenses biomaterials derived from modified hyaluronic acid (HA) using its proprietary Hyaluromimethic® technology platform, which performs covalent modification of HA at hydroxyl residues with functional, biologically active molecules. This produces a modular family of derivatives including Sodium Hyaluronate Butyrate (SHB), Sodium Hyaluronate Lipoate (SHL), Sodium Hyaluronate Lipoate Formate (SHLF), and Zinc-Gluconate combinations, each with distinct physicochemical properties tailored for specific applications. The company holds 140 patents across 9 patent families and 6 international brands, and operates four business units: BMG Biochemical (raw materials, recently spun off as an independent entity), BMG Bioaesthetic (Class III injectable aesthetic devices), BMG Therapeutics (Class III injectable orthopedic and ophthalmological devices including SGA400), and BMG Dermacare (professional cosmetic products under the HYALUVANCE® brand).

The business operates an asset-light B2B model combining raw materials supply, technology licensing, and co-development partnerships with international pharmaceutical and cosmetic companies. Production of finished products and clinical consultancy are outsourced to contract manufacturing organizations (CMOs), while marketing is conducted through international distribution partners. The customer base spans oral care (Dompè, Pierre Fabre, ISDIN, Polifarma, Bionativa, Sophos, Galen, Diomed Dermal), dermatology (Difa Cooper, Dr Gorkic), and aesthetic medicine, with finished products marketed under partner brands such as Euclorina, Elgydium, Bexident, Emoform, and GelX. The company's go-to-market combines enterprise field sales to pharma partners with direct engagement of health professionals (aesthetic doctors, nurses) for the HYALUVANCE® professional cosmetic line.

Current commercial focus is on scaling the Class III injectable pipeline (six dermal fillers and one orthopedic injectable in clinical/MDR regulatory stages in Europe), launching HYALUVANCE® Golden for aesthetic medicine mesotherapy, and licensing the Hyaluromimethic® platform to global pharmaceutical partners. The company is ISO 13485 certified and pursues European MDR registration through Notified Bodies TÜV and Eurofins. Revenue figures are not publicly disclosed, and the company remains privately held following minority investments from Massimo Doris (CEO of Banca Mediolanum, 2% stake acquired November 2022) and Friulia Finanziaria FVG (regional PE firm, ~$2.4M round in 2021).

BMG Pharma firmographics

Firmographics
Name
BMG Pharma
Legal name
BMG Pharma SpA
Website
https://bmgpharma.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
BMG Pharma is an Italian pharmaceutical company that develops and licenses proprietary modified hyaluronic acid biomaterials (Hyaluromimethic® platform) through B2B partnerships with global pharmaceutical and cosmetic companies serving aesthetic, orthopedic, ophthalmic, dermatological, and oral care markets.
Ownership category
akta.pro rank

BMG Pharma industry classification

Industry
Product category
Biopharmaceuticals & Medical Devices
NAICS
Pharmaceutical Preparation Manufacturing (325412), Surgical and Medical Instrument Manufacturing (339112)
SIC
Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYIMANABAK
Medical & Food-Contact Specialty Compounds

Keywords

  • Hyaluronic acid biomaterials
  • Pharmaceutical product development
  • Medical device manufacturing
  • Biotechnology licensing
  • Aesthetic medicine products

Where BMG Pharma is headquartered

Location

Headquarters

HQ city
Milan
HQ country
Italy
HQ region
Europe

Offices2 records

Markets served

BMG Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing/Property: Patents; ISO 13485 TUV Sud certification for medical devices; Know-how and technology licensing. Hyaluronic acid derivatives production plant; Marketing of raw materials through collaborations with international pharmaceutical companies.
  2. Aesthetic Applications Products: Licensing of aesthetic applications of injectable products based on hyaluronic acid butyrate derivatives (SHB) and lipoates (SHLF) with the international brand Hyaluromimethic®. 6 dermal fillers undergoing clinical trials and MDR registration in Europe.
  3. Orthopaedic Applications: Licensing of orthopaedic applications of injectable products based on hyaluronic acid lipoate derivative (SHLF). 1 injectable in preclinical investigation phase for MDR registration.
  4. Professional Cosmetics: Sale of cosmetics for professional use by aesthetic doctors with the international proprietary brand HYALUVANCE®. HYALUVANCE® GOLDEN available for marketing.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

BMG Pharma product offering

Product offering

Core offering

BMG Pharma develops, manufactures, and licenses innovative biomaterials based on its proprietary Hyaluromimethic® technology platform, which enables covalent modification of hyaluronic acid at hydroxyl residues with functional, biologically active molecules. The company produces hyaluronic acid derivative raw materials (SHB, SHL, SHLF, SHLFZ), Class III injectable medical devices (SGA400 for osteoarthritis; dermal fillers), and professional cosmetic products (HYALUVANCE® line for aesthetic medicine), serving global pharmaceutical partners and health professionals through licensing, contract manufacturing, and direct distribution.

Product overview

BMG Pharma is a pharmaceutical company with over 15 years of experience developing and partnering internationally on innovative medical products. The company has developed the proprietary Hyaluromimethic® technology platform for covalent modification of hyaluronic acid, which serves as the foundation for its product ecosystem. The portfolio includes four business units: BMG Biochemical (chemical technology hub producing functional ingredients and raw materials like SHB, SHL, SHLF derivatives), BMG Bioaesthetic (Class III injectable medical devices for aesthetic medicine), BMG Therapeutics (Class III injectable medical devices for orthopedics and ophthalmology, including SGA400), and BMG Dermacare (professional topical cosmetic products under the HYALUVANCE® brand including HYALUVANCE® Golden). The company also licenses its technology and holds 140 patents across 9 families globally.

Differentiator

Problem solved

Functional benefit

Brands

  • HYALUVANCE®: International brand for professional cosmetic products for aesthetic medicine, including sterile topical products and the HYALUVANCE® GOLDEN line based on milk exosomes, type 3 collagen, and polynucleotides
  • Hyaluromimethic®
  • SGA400
  • BMG Biochemical
  • BMG Bioaesthetic
  • BMG Therapeutics
  • BMG Dermacare

Products and services

  • Hyaluromimethic® Technology Platform Proprietary patented technology platform for covalent modification of hyaluronic acid at hydroxyl residues with functional, biologically active molecules. Licensed to pharmaceutical partners for the development of biomaterials, medical devices, and cosmetic products in aesthetic, orthopedic, ophthalmological, and dermatological applications.
  • SGA400 Class 3 medical injectable based on Hyaluromimethic® technology for intraarticular therapy. Provides long intra-articular permanence, absorption of mechanical stress, modulation of inflammation and free radicals, and pain management for patients suffering from joint osteoarthritis.
  • HYALUVANCE® Golden Sterile cosmetic vials (5x3ml) for professional use in aesthetic medicine. Based on milk exosomes, type 3 collagen, polynucleotides (PDRN), and high molecular weight hyaluronic acid. Indicated for skin rejuvenation mesotherapy treatments.
  • HYALUVANCE® Professional Cosmetics Line International proprietary brand under which a new pipeline of professional cosmetic products for aesthetic medicine is being built. Includes sterile topical products distributed through BMG Dermacare for medical professionals offering innovative aesthetic treatments.
  • Hyaluronic Acid Derivative Raw Materials (SHB, SHL, SHLF, SHLFZ) Functional hyaluronic acid derivative raw materials produced by BMG Biochemical and supplied to pharmaceutical partners. Includes Sodium Hyaluronate Butyrate (SHB), Sodium Hyaluronate Lipoate (SHL), Sodium Hyaluronate Lipoate Formate (SHLF), and Sodium Hyaluronate Lipoate Formate and Zinc Gluconate (SHLFZ) — each with distinct functional properties for dermatology, tissue repair, aesthetic, and medical applications.
  • Hyaluromimethic® Dermal Fillers Pipeline (6 products in clinical trials/MDR registration) Licensed aesthetic application injectable products based on Hyaluromimethic® hyaluronic acid derivatives (SHB and SHLF). Six dermal fillers currently in clinical trials and MDR registration in Europe for aesthetic dermatology and biorevitalization applications.

Quantifiable outcome

  • 4 new patents created and 36 innovative products registered, 37 launched internationally in two years
  • +1 more outcomes

Companies that use BMG Pharma

Customer profile

Named customers10 records

Segments6 records

Ideal customer profiles3 records

BMG Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

BMG Pharma partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • Allianz PowerVolley MilanominorOthers · 3 April 2026BMG Pharma has always supported Allianz PowerVolley Milano volleyball team. The team won the 2026 CEV Challenge Cup. The company aims to bring prominent volleyball back to Milan.
  • HTL BiotechnologycoreTechnology or Integration · 15 September 2022BMG Pharma and HTL Biotechnology signed an agreement for the production of the functional ingredient underlying the patented Hyaluromimethic® technology. This partnership ensures production capability for the exclusive technology platform.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

BMG Pharma competitors and assessment

Company assessment

Emerging players

  • Dompé Farmaceutici: Italian pharma with a board connection to BMG and a disclosed BMG customer using its ingredients in oral-care ranges. Comparable as a like-for-like Italian specialty pharma and existing commercial partner for BMG's technology.
  • Revance Therapeutics: US aesthetics-focused biotech whose portfolio includes the RHA Collection of hyaluronic acid fillers following the Teoxane US acquisition. Comparable business model — innovator aesthetics platform leveraging differentiated HA technology — to BMG Bioaesthetic.

Broad incumbents

  • Galderma: Global dermatology and aesthetic medicine leader selling hyaluronic-acid-based dermal fillers (Restylane, Emervel) and prescription aesthetics. Directly comparable to BMG Bioaesthetic and HYALUVANCE® as the incumbent BMG is trying to disrupt in fillers and professional aesthetic skincare.
  • Merz Aesthetics: Subsidiary of Merz Pharma marketing hyaluronic acid fillers (Belotero), biostimulators and medical skincare. Competes head-on with BMG Bioaesthetic and HYALUVANCE® in clinic-administered aesthetics.

Direct peers

  • Fidia Farmaceutici: Italian specialty pharma whose hyaluronic acid-based products (e.g. Hyalgan, Hymovis) cover intra-articular osteoarthritis therapy and aesthetic medicine. Direct category overlap with BMG Therapeutics' SGA400 and the BMG Bioaesthetic injectable line.
  • Sinclair Pharma: Aesthetic medicine company previously LSE-listed, founded by BMG's current CEO Marco Mastrodonato. Sells hyaluronic-acid dermal fillers and collagen-stimulating injectables (e.g. Ellansé, MaiLi). Same hyaluronic-acid-based injectable franchise, same end customer (aesthetic physicians), making it the closest direct comparable.
  • Teoxane Laboratories: Swiss manufacturer of hyaluronic acid-based dermal fillers (Teosyal RHA range) and professional cosmeceuticals. Overlaps with BMG Bioaesthetic's injectable pipeline and HYALUVANCE® professional skincare in the same clinician-administered channel.
  • Anika Therapeutics: US-based developer of hyaluronic acid-based intra-articular and regenerative products (e.g. Monovisc, Orthovisc, Cingal) for osteoarthritis and tendon repair, plus aesthetic HA offerings. The cleanest US analog to BMG Therapeutics' SGA400 program.
  • IBSA Farmaceutici: Italian private pharma company with a substantial hyaluronic acid portfolio including intra-articular injectables for osteoarthritis and aesthetic dermatology products. Closely comparable to BMG Therapeutics (SGA400 osteoarthritis injectable) and BMG Bioaesthetic.

Others

  • HTL Biotechnology: French-Japanese specialist manufacturer of high-purity hyaluronic acid for medical and aesthetic applications. Signed a 2022 production agreement with BMG, making it a critical supplier/partner rather than a competitor, but a highly relevant comparable for understanding HA ingredient economics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

BMG Pharma social profiles

Digital presence

BMG Pharma compliance and trust

Trust signal

Compliance2 records

BMG Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BMG Pharma leadership team

Management profile

Number of profiles

Profiles7 records

BMG Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

BMG Pharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BMG Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BMG Pharma

What does BMG Pharma do?

BMG Pharma develops, manufactures, and licenses innovative biomaterials based on its proprietary Hyaluromimethic® technology platform, which enables covalent modification of hyaluronic acid at hydroxyl residues with functional, biologically active molecules. The company produces hyaluronic acid derivative raw materials (SHB, SHL, SHLF, SHLFZ), Class III injectable medical devices (SGA400 for osteoarthritis; dermal fillers), and professional cosmetic products (HYALUVANCE® line for aesthetic medicine), serving global pharmaceutical partners and health professionals through licensing, contract manufacturing, and direct distribution.

Is BMG Pharma a public or private company?

BMG Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was BMG Pharma founded?

BMG Pharma was founded in 2011. It employs 11 to 50 people.

Where is BMG Pharma based?

BMG Pharma is headquartered in Milan, Italy, in the Europe region.

How does BMG Pharma make money?

Four revenue lines are on record. Licensing/Property is the primary driver. The others are aesthetic Applications Products, orthopaedic Applications and professional Cosmetics.

Who are BMG Pharma's main competitors?

Emerging players on record are Dompé Farmaceutici and Revance Therapeutics. Broad incumbents are Galderma and Merz Aesthetics. Direct peers are Fidia Farmaceutici, Sinclair Pharma, Teoxane Laboratories, Anika Therapeutics and IBSA Farmaceutici. HTL Biotechnology is listed as an others.

Does BMG Pharma have an API?

No public API is recorded for BMG Pharma.

What industry is BMG Pharma in?

BMG Pharma's product category is Biopharmaceuticals & Medical Devices. Its primary akta.pro industry code is HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals, with a secondary code of HLAIAAAL, Ophthalmology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals